Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease

Non-myeloablative allogeneic transplant (NMAT) has a curative potential for patients who are not myeloablative allogeneic transplant (MAT) candidates. We report a phase II trial of a NMAT regimen with cyclophosphamide and fludarabine in 40 patients; 21 of whom had a prior MAT. Day +100 and 1-year tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Paplham, Pamela, Hahn, Theresa, Dubel, Karen, Lipka, Patricia, McCarthy, Philip L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055986/
https://www.ncbi.nlm.nih.gov/pubmed/24936405
http://dx.doi.org/10.1016/j.lrr.2014.03.001
Descripción
Sumario:Non-myeloablative allogeneic transplant (NMAT) has a curative potential for patients who are not myeloablative allogeneic transplant (MAT) candidates. We report a phase II trial of a NMAT regimen with cyclophosphamide and fludarabine in 40 patients; 21 of whom had a prior MAT. Day +100 and 1-year transplant-related mortality (TRM) post-NMAT were 13% and 34%, respectively. Day +100 and 1-year Overall/Progression-Free Survival (OS/PFS) were 80%/65% and 43%/25%, respectively. OS was higher in patients with KPS≥90 and lower in recipient/donor CMV+/− vs. other combinations. FluCy has low TRM and is curative in about 20% of high-risk patients.

Ejemplares similares